- Home
- INMB vs ABOS Comparison
INMB vs ABOS Comparison
Compare INMB & ABOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INMB
- ABOS
- Stock Information
- Founded
- INMB 2015
- ABOS 1996
- Country
- INMB United States
- ABOS United States
- Employees
- INMB N/A
- ABOS N/A
- Industry
- INMB Biotechnology: Pharmaceutical Preparations
- ABOS Biotechnology: Pharmaceutical Preparations
- Sector
- INMB Health Care
- ABOS Health Care
- Exchange
- INMB Nasdaq
- ABOS Nasdaq
- Market Cap
- INMB 68.9M
- ABOS 82.4M
- IPO Year
- INMB 2019
- ABOS 2021
- Fundamental
- Price
- INMB $2.53
- ABOS $1.42
- Analyst Decision
- INMB Buy
- ABOS Strong Buy
- Analyst Count
- INMB 4
- ABOS 3
- Target Price
- INMB $9.53
- ABOS $6.33
- AVG Volume (30 Days)
- INMB 2.9M
- ABOS 314.6K
- Earning Date
- INMB 08-07-2025
- ABOS 08-12-2025
- Dividend Yield
- INMB N/A
- ABOS N/A
- EPS Growth
- INMB N/A
- ABOS N/A
- EPS
- INMB N/A
- ABOS N/A
- Revenue
- INMB $50,000.00
- ABOS N/A
- Revenue This Year
- INMB $212.27
- ABOS N/A
- Revenue Next Year
- INMB $10,184.28
- ABOS N/A
- P/E Ratio
- INMB N/A
- ABOS N/A
- Revenue Growth
- INMB N/A
- ABOS N/A
- 52 Week Low
- INMB $1.89
- ABOS $0.86
- 52 Week High
- INMB $11.64
- ABOS $3.36
- Technical
- Relative Strength Index (RSI)
- INMB 41.61
- ABOS 53.03
- Support Level
- INMB $2.42
- ABOS $1.24
- Resistance Level
- INMB $2.61
- ABOS $1.50
- Average True Range (ATR)
- INMB 0.22
- ABOS 0.11
- MACD
- INMB 0.09
- ABOS -0.01
- Stochastic Oscillator
- INMB 26.67
- ABOS 56.10
About INMB INmune Bio Inc. Common stock
INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products include INKmune, INBO3, XPro1595, LIVNate, and others.
About ABOS Acumen Pharmaceuticals Inc.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.